Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Bambuser AB Publishes Interim Report for Q2 2021

For the second consecutive quarter, Bambuser experienced its best results since inception. In addition to strong global demand, the company continues to grow its relationships with large enterprises and conglomerates, resulting in a sales lift of +664 percent. During the quarter, Bambuser saw an increasing number of contracts with terms of 12 to 36 months, while also converting existing pilot and proof of concept agreements to long-term agreements. As a result, the Company saw a significant increase in monthly recurring revenue (MRR), which grew +263 percent compared to Q2 2020. The interim

Veoneer Files Preliminary Proxy in connection with Magna merger agreement

Stockholm, Sweden, August 20, 2021 – The automotive technology company Veoneer, Inc. (NYSE: VNE and SSE: VNE SDB), today announced that it has, as part of the process following the previously announced merger agreement with Magna International Inc. (TSX: MG; NYSE: MGA), filed a preliminary proxy statement with the Securities and Exchange Commission (the “SEC”).The preliminary proxy statement is not complete and is subject to amendment. When available, a definitive proxy statement is expected to be sent to Veoneer stockholders in connection with a special meeting of Veoneer stockholders.

Bambuser's Nomination Committee proposes that Sonia Gardner and Jørgen Madsen Lindemann be elected as new board members – Alexander Mcintyre has announced his intention to resign from the board

  To further strengthen the board of directors competence the Nomination Committee of Bambuser proposes that Sonia Gardner and Jørgen Madsen Lindemann, respectively, be elected as new board members of Bambuser. At the same time, Alexander Mcintyre has announced that he intends to resign from the board of directors. In light of the Nomination Committee's proposal, the board of directors intends to convene an Extraordinary General Meeting whereas the notice will be published separately. Alexander Mcintyre will leave the board of directors in connection to the Extraordinary

Nel ASA: Employee share option program

(Oslo, 19 August 2021) Nel ASA has today resolved to grant options to all employees of the company that fulfil the requirements for participation in the employee share option plan. The grant of options is based on the authorization from Nel’s annual general meeting (AGM) of 15 April 2021 to issue new shares in connection with Nel’s incentive plan for employees, and the same AGM’s adoption of the statement of the board regarding long-term incentive plans A total number of 7,768,464 share options were granted in a groupwide program comprising all employees in Nel fulfilling certain

Tine Kold Olesen will join Biosergen AB as Chief Operating Officer

Thursday, August 19, 2021: Biosergen  AB (“Biosergen” or the “Company”) today announced that it has appointed Tine Kold Olesen as COO of Biosergen. Tine Kold Olesen (MSc, MBA, PhD) has an impressive resume in international drug developmentBiosergen’s CEO Peder M. Andersen comments: “I am very pleased that we have been able to attract an international capacity like Tine Kold Olesen as our new Chief Operating Officer. Tine is a hands-on drug developer who is able to focus on the details while still keeping the overall objectives and long term strategies in sight. This is exactly what we

MUSTI GROUP PLC: Share Repurchase 19.8.2021

Musti Group Stock Exchange Release 19.8.2021 MUSTI GROUP PLC: Share Repurchase 19.8.2021 In the NASDAQ OMX Helsinki Trade date           19.8.2021Bourse trade         BuyShare                  MUSTIAmount             11 000 SharesAverage price/ share    31,4837 EURTotal cost            346 320,70 EUR Company now holds a total of 205 000 sharesincluding the shares repurchased on 19.8.2021 On behalf of Musti Group Nordea Bank Finland Plc Janne Sarvikivi

Release of application and dermatological test results for CANNASEN CBD Psoriasis lotion

Today, August 19[th], 2021, CS MEDICA A/S’s (”CS MEDICA” or the ”Company”) announces a good result on two tests performed at the Dermatology Clinic of the Medical University of Gdańsk, an application test and a dermatological test on the Company’s Psoriasis lotion.Lone Henriksen comments “Irritating and allergenic properties. We are very excited about these positive results as it follows our targets in preparation for the market launch of the product in H1 2021/2022.” These results confirm that Psoriasis lotion show positive effects and can be used as an adjunctive treatment product. It

Corem controls 98.5 per cent of the outstanding shares in Klövern

The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in any jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. For further information, please see the section "Important information" below.On 29 March 2021, Corem Property Group AB (

Adapteo Plc: Notification of major holdings in accordance with Chapter 9, Section 10 of the Securities Markets Act

Adapteo Plc Regulatory press release  19 August 2021 at 16:45 CEST Adapteo Plc (the "Company") has received on 19 August 2021 the following notification pursuant to Chapter 9, Section 5 of the Securities Markets Act (the "SMA") from Palace Bidco Oy. According to the notification, the holding of Palace Bidco Oy in the Company's shares and votes has exceeded the threshold of ninety (90) per cent on 18 August 2021. According to the notification, the reason for the notification was an acquisition of shares or voting rights. Total position of Palace Bidco Oy in the Company according to

Max Ortiz Catalán appointed Professor of Bionics, Department of Electrical Engineering, Chalmers University of Technology, Gothenburg, Sweden.

Integrum extends its warmest congratulations to Max Ortiz Catalán, Ph.D. He is former Head of Research and Development at Integrum AB, the Founder and Director of the CBPR  (Center for Bionics and Pain Research), and has now been appointed Professor of Bionics at the Department of Electrical Engineering , Chalmers University of Technology. While Head of R&D at Integrum, Max Ortiz Catalán worked closely with Chalmers and Sahlgrenska University Hospital, and was

#21-277 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

#21-276 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

BEWiSynbra announces the results of the written procedures instigated on 9 August 2021

BEWiSynbra Group AB (publ) (the “Issuer”) today announces the results of the written procedures instigated through the agent Nordic Trustee & Agency AB (publ) (the “Agent”) on 9 August 2021 (the “Written Procedures”) relating to its up to EUR 100,000,000 Senior Secured Floating Rate Notes due 2022 (ISIN: SE0010985556) and its up to EUR 115,000,000 Senior Secured Floating Rate Notes due 2023 (ISIN: SE0013409455) (collectively referred to as the “Bonds”). As further described in the notices of written procedure published by the Issuer and the Agent, respectively, on 9 August 2021 (the “

BEWI ASA confirms intention to refinance the senior secured floating rate bonds issued by BEWiSynbra Group AB (publ)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933), AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. On 9 August 2021, BEWI ASA (the “Issuer”) announced its intention to refinance the up to EUR 100,000,000 Senior

Invitation to phone conference with webcast in conjunction with the release of the Instalco Q2 2021 report

Instalco will release its Interim report Q2 2021 on 25 August at 11:00 CET. Instalco will also be presenting the report in a phone conference with webcast at 14:00 on the same day.Per Sjöstrand, CEO and Robin Boheman, CFO will be presenting and commenting on the report. Publication of the Q2 2021 report 11:00 CEThttps://instalco.se/en/investors/financial-reports Phone numbers for joining the telephone conference at 14:00 CETSE: +46 8 566 427 07UK: +44 33 33 00 92 71US: +1 646 722 49 56 Link to the webcast, 14:00 CEThttps://tv.streamfabriken.com/instalco-q2-2021 The

Immunovia Publishes Report for the Second Quarter 2021

LUND (SWEDEN) – Immunovia AB (publ) (“Immunovia”) has today published its report for the second quarter 2021. It is available on Immunovia’s website.  Patrik Dahlen, CEO: “We started the quarter by applying for a Massachusetts State License and CLIA Certification of the Immunovia, Inc. laboratory in Marlborough. After the period we received final approval to start patient testing with IMMray™ PanCan-d in the US. We are now very pleased to have received the final approval of our laboratory and that we now can launch the IMMray™ PanCan-

Distribution of shares as part of the savings scheme for employees

The shares purchased by SpareBank 1 SR-Bank ASA 12 August, 13 August and 16 August 2021 for use in the group's savings scheme for employees, have been distributed to the employees at a price of NOK 122,04957. After allocation the banks total holding of own shares is 41 273 shares. As participants in the savings scheme the primary insiders have acquired shares in accordance with the enclosed list.  The information is subject to the disclosure requirements set out in section 5 -12 of the Norwegian Securities Trading Act.

Potential treatment break-through in patients with severe bladder pain

The successful outcome of a new treatment approach is now reported for patients with severe bladder pain. The publication presents data showing that an IL-1 receptor antagonist (IL-1RA) reduces pain and increases the quality of life in this severely handicapped patient group. Preliminary findings were reported in 2020.The results are published in European Urology Open Science, a leading journal in the field of urology that publishes international discoveries with clinical relevance (Wullt et al. 2021. Immunomodulation - A Molecular Solution to Treating Patients with Severe Bladder Pain

TOMRA: Mandatory notification of trade

Mads Hultgreen, primary insider of TOMRA Systems ASA and person closely associated to Tove Andersen, President and CEO of TOMRA Systems ASA, has today bought 2,000 shares in TOMRA Systems ASA at a price of NOK 509.68 per share. After the transaction Mads Hultgreen holds 2,000 shares in TOMRA Systems ASA.   This information is subject to the disclosure requirements in Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act § 5-12.

Scandi Standard – Second quarter presentation

Scandi Standard will publish its report for the second quarter 2021 on Wednesday, 25 August 2021 at 07.30 CET. Conference call at 08.30 CETThe Company will host a conference call for the financial community at 08.30 CET the same day.The conference call will be hosted by Otto Drakenberg, CEO and Julia Lagerqvist, CFO. Dial in numbers: Sweden 0800 640 6441Sweden (Local) 0200 123 717United Kingdom 0800 640 6441United Kingdom (Local) 020 3936 2999USA 1 855 9796 654USA (Local) 1 646 664 1960All other

BioStock: Alligator Bioscience enters collaboration with Orion Corporation

We found out this week that Alligator Bioscience’s immuno-oncology technology platform RUBY has caught the eye of Orion Corporation, a global pharma company dedicated to developing new treatments for cancer patients. The research collaboration signed between the two companies will focus on the discovery of novel bispecific antibodies directed towards immuno-oncology targets selected by Orion.Read the article at biostock.se: https://www.biostock.se/2021/08/alligator-bioscience-enters-collaboration-with-orion-corporation/ This is a press release from BioStock - Connecting Innovation &

BioStock: Cereno Scientific enters collaboration with Abbott

Swedish biopharma company Cereno Scientific has taken yet another important step towards initiating a phase II clinical trial with lead programme CS1 by entering into a collaboration agreement with global healthcare company Abbott. The agreement stipulates that Cereno Scientific will use Abbott’s CardioMEMS HF System in the upcoming phase II trial to remotely and continuously monitor the pulmonary pressure in pulmonary arterial hypertension patients being treated with CS1.Read the article at biostock.se: https://www.biostock.se/en/cereno-scientific-enters-collaboration-with-abbott/

EQT Infrastructure V to co-invest in EdgeConneX

EQT Infrastructure V has signed an agreement to co-invest alongside EQT Infrastructure IV in EdgeConneX (“the Company”). Once the transaction is complete, each fund will have an equal ownership stake in the Company. EdgeConneX is a fast-growing data center platform focusing on demand from the cloud-, content-, and network customer ecosystem, and the Company offers a differentiated combination of hyperscale and edge data centers. Following the acquisition by EQT Infrastructure IV in 2020, additional growth and development opportunities have been identified, such as winning additional

There are no items matching the current filter
There are no more items matching the current filter
Back to top